Immunogenicity and Safety of Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Potential Hajj/Umrah Pilgrims Aged ≥ 56 Years: A Phase III, Open-Label Study

Key Points

• The quadrivalent meningococcal conjugate vaccine shows significant immunogenicity in participants aged 56 and older, ensuring robust protection against meningococcal disease.
• Safety assessments reveal that the vaccine is well-tolerated with minimal adverse effects, promoting confidence among older pilgrims during travel.
• This open-label study utilizes a Phase III design, confirming the vaccine's efficacy in a real-world population of potential Hajj participants.
• The findings support the inclusion of the vaccine in immunization schedules for older travelers to high-risk areas, particularly during Hajj and Umrah.